logo-loader
viewNetscientific PLC

NetScientific says portfolio company Vortex signs partnership deal with cell imaging firm BioView

The AIM-listed firm said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care

laboratory
BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions

NetScientific PLC (LON:NSCI) revealed that its portfolio company Vortex BioSciences has signed a collaboration deal with BioView Ltd, a provider of automated cell imaging and analysis solutions with the aim of providing clinicians with deeper insights into cancer biology.

The AIM-listed transatlantic biomedical and healthcare IP commercialisation group said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool.

READ: NetScientific announces first sale of point-of-care test from portfolio company

BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions.

Francois Martelet, NetScientific's CEO and chairman of Vortex, said: “This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex’s platform.”

He concluded: “This technology has potential applications in the fast-evolving field of immuno-oncology and the collaboration represents a critical step for Vortex as it moves towards the clinical market.”

Quick facts: Netscientific PLC

Price: 2.7 GBX

AIM:NSCI
Market: AIM
Market Cap: £2.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read